logo-loader
viewInnoCan Pharma

InnoCan Pharma names medical device CEO to its board of directors

Peter Bloch is CEO of Bresotec, which develops sleep apnea devices

Boardroom
Bloch is replacing outgoing director Daryl Fridhandler, who resigned this week

InnoCan Pharma (CSE:INNO) announced that Peter Bloch, the CEO of medical device developer Bresotec Inc, has joined its board of directors.

Prior to leading Bresotec, Bloch was CEO and chairman of Bionik Laboratories Corp (OTCMKTS:BNKL), a prosthetics company based in Toronto. He’s also held senior management roles at Sanofi-Aventis Canada, Intellivax International Inc., Gennum Corporation and Tribute Pharmaceuticals.

"We welcome Peter to the InnoCan Board,” CEO Iris Bincovich said in a statement. “Peter's unique combination of experience as an officer of mature companies and as the leader of start up companies along with his extensive healthcare/biotech background will be an invaluable resource for InnoCan. 

READ: InnoCan Pharma's injectable CBD research project with Hebrew University advances

Also, North America is a top market for InnoCan Pharma and Peter will be a key advisor as we enter 2020 implementing our full commercialization strategy," Bincovich added.

Bloch replaces outgoing director Daryl Fridhandler, who resigned this week. Eyal Flom, another director, has taken on Fridhandler’s role as corporate secretary.

InnoCan Pharma, based in Israel, is developing a platform that enables the controlled release of CBD using injections of liposomes, a vesicle with a structure that resembles cell membranes.

Shares in Canada surged 22.22% to C$0.11.

---Updates for share price---

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: InnoCan Pharma

Price: 0.085 CAD

CSE:INNO
Market: CSE
Market Cap: $12.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Innocan signs deal with Hebrew university while also signing...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver from Toronto with news the company has signed a deal with the distribution company Active Therapeutics. This agreement allows Innocan to move into the U.K. and Ireland.  Bincovich also told...

2 weeks, 5 days ago

2 min read